The latest price target for Vertex Pharmaceuticals (NASDAQ:VRTX) was reported by Barclays on December 20, 2024. The analyst firm set a price target for $418.00 expecting VRTX to rise to within 12 months (a possible 5.36% upside). 74 analyst firms have reported ratings in the last year.

The latest analyst rating for Vertex Pharmaceuticals (NASDAQ:VRTX) was provided by Barclays, and Vertex Pharmaceuticals maintained their equal-weight rating.

The last upgrade for Vertex Pharmaceuticals Inc happened on December 9, 2024 when Jefferies raised their price target to $550. Jefferies previously had a hold for Vertex Pharmaceuticals Inc.

The last downgrade for Vertex Pharmaceuticals Inc happened on August 5, 2024 when Barclays changed their price target from $472 to $509 for Vertex Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vertex Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vertex Pharmaceuticals was filed on December 20, 2024 so you should expect the next rating to be made available sometime around December 20, 2025.

While ratings are subjective and will change, the latest Vertex Pharmaceuticals (VRTX) rating was a maintained with a price target of $509.00 to $418.00. The current price Vertex Pharmaceuticals (VRTX) is trading at is $396.74, which is out of the analyst’s predicted range.